Fluorine-18 2-Fluoro 2-deoxyglucose ( [18] F FDG) positron emission tomography and computed tomography (PET/CT) is a powerful imaging tool for cancer detection and monitoring response to therapy in various malignancies. However, evaluation of response to therapy may be negatively influenced by its non-specificity (uptake in inflammatory/reactive cells). [18] F-labeled dimeric RGD peptide [^?F] FPA-PEG3-E[c(RGDyK)]2 ( [18] F] FPPRGD2), a novel radiopharmaceutical recently developed at Stanford for imaging of tumor integrin expression, may provide more accurate evaluation of response to anti-angiogenesis therapy in subjects with lung cancer. We already successfully performed small animal imaging studies demonstrating the feasibility of [ [18] F] FPPRGD2 PET imaging and the possibility to monitor response to anti-angiogenesis therapy. The first in human (healthy volunteer) administration of [ [18] F] FPPRGD2 followed by PET/CT was already done on June 22, 2009. Magneto-nano protein chips (magnetic chips) enable protein profiling of mouse or human serum samples in a high throughput and multiplexed format, and represent an exciting, powerful tool for exploring many facets of the signaling pathway network in cancer. The vascular endothelial growth factor (VEGF) and human epidermal growth factor receptor (HER-1/EGFR) have been identified as key molecular targets for therapy in non-small-cell lung cancer (NSCLC). Conventional tumor imaging with contrast enhanced CT relies on changes in size to evaluate response to therapy. However, targeted therapies may not cause a significant change in the size of the lesions. Therefore, functional molecular imaging may provide earlier and more accurate means of assessing response to these new drugs. Based on the promising preliminary preclinical results we will attempt to recruit 50 subjects with NSCLC to investigate the hypotheses that [[18] F] FPPRGD2 PET/CT is feasible and that in combination with magnetonano sensors measurements of EGFR pathways can assess and predict the response to targeted Tarceva/Avastin or Vandetanib therapy in NSCLC.
Aim 1 : Evaluate the efficacy and feasibility of f [18] F] FPPRGD2 PET/CT scanning in patients with NSCLC.
Aim 2 : Evaluate the combination of [ [18] F] FPPRGD2 PET/CT and magneto-nano sensors for early assessment and prediction of response to Tarceva/Avastin or Vandetanib therapy in patients with NSCLC.

Public Health Relevance

The introduction of targeted therapy in NSCLC such as Tarceva/Avastin or Zactima warrants the development and validation of novel non-invasive methods to predict and assess response to such treatments, beyond the current imaging methods relying on changes in anatomy. We identified and tested in small animal studies a new PET radiopharmaceutical targeting integrins expression and plan on using It in human subjects with NSCLC In order to predict and evaluate response to anti-angiogenesis drugs. This will be done in combination with another novel approach using magneto-nanosensors to detect changes in proteins indicative of response to EGFR TK inhibitors in NSCLC. This may result in improved patient care and significant reduction in healthcare costs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Chang, Edwin; Liu, Hongguang; Unterschemmann, Kerstin et al. (2015) 18F-FAZA PET imaging response tracks the reoxygenation of tumors in mice upon treatment with the mitochondrial complex I inhibitor BAY 87-2243. Clin Cancer Res 21:335-46
Ye, Deju; Shuhendler, Adam J; Pandit, Prachi et al. (2014) Caspase-responsive smart gadolinium-based contrast agent for magnetic resonance imaging of drug-induced apoptosis. Chem Sci 4:3845-3852
Casey, Stephanie C; Li, Yulin; Felsher, Dean W (2014) An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation. Immunol Res 58:282-91
Pu, Kanyi; Shuhendler, Adam J; Valta, Maija P et al. (2014) Phosphorylcholine-coated semiconducting polymer nanoparticles as rapid and efficient labeling agents for in vivo cell tracking. Adv Healthc Mater 3:1292-8
Bu, Lihong; Shen, Baozhong; Cheng, Zhen (2014) Fluorescent imaging of cancerous tissues for targeted surgery. Adv Drug Deliv Rev 76:21-38
Lazari, Mark; Collins, Jeffrey; Shen, Bin et al. (2014) Fully automated production of diverse 18F-labeled PET tracers on the ELIXYS multireactor radiosynthesizer without hardware modification. J Nucl Med Technol 42:203-10
Cheng, Kai; Kothapalli, Sri-Rajasekhar; Liu, Hongguang et al. (2014) Construction and validation of nano gold tripods for molecular imaging of living subjects. J Am Chem Soc 136:3560-71
Do, John; Foster, Deshka; Renier, Corinne et al. (2014) Ex vivo Evans blue assessment of the blood brain barrier in three breast cancer brain metastasis models. Breast Cancer Res Treat 144:93-101
Fan, Quli; Cheng, Kai; Hu, Xiang et al. (2014) Transferring biomarker into molecular probe: melanin nanoparticle as a naturally active platform for multimodality imaging. J Am Chem Soc 136:15185-94
Levi, Jelena; Sathirachinda, Ataya; Gambhir, Sanjiv S (2014) A high-affinity, high-stability photoacoustic agent for imaging gastrin-releasing peptide receptor in prostate cancer. Clin Cancer Res 20:3721-9

Showing the most recent 10 out of 314 publications